-
-
-
-
-
-
-
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
-
-
-
-
-
-
-
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
-
-
-
-
-
-
-
ProKidney Corp (PROK) Announces Leadership Changes
-
-
-
-
-
-
-
ProKidney (PROK) Reports Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy
-
-
-
-
-
-
-
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
-
-
-
-
-
-
-
ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
-
-
-
-
-
-
-
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chroni
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

